Veracyte (VCYT) Receivables (2012 - 2026)

Veracyte (VCYT) has 15 years of Receivables data on file, last reported at $50.1 million in Q1 2026.

• Quarterly Receivables fell 6.82% year-over-year to $50.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.1 million (down 6.82% YoY) and the FY2025 annual result came in at $44.7 million, down 4.01% from the prior year.
• Receivables rose to $50.1 million in Q1 2026 per VCYT's latest filing, from $44.7 million in the prior quarter.
• The five-year high for Receivables was $53.8 million in Q1 2025, with the low at $39.3 million in Q3 2023.
• Average Receivables over 5 years is $45.5 million, with a median of $45.5 million recorded in 2023.
• Year-over-year, Receivables surged 52.39% in 2022 and decreased 8.28% in 2023.
• Veracyte's Receivables stood at $44.0 million in 2022, then retreated by 8.28% to $40.4 million in 2023, then climbed by 15.22% to $46.5 million in 2024, then slipped by 4.01% to $44.7 million in 2025, then advanced by 12.21% to $50.1 million in 2026.
• Business Quant data shows VCYT's Receivables at $50.1 million in Q1 2026, $44.7 million in Q4 2025, and $47.8 million in Q3 2025.